- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
Patent holdings for IPC class A61P 25/30
Total number of patents in this class: 1114
10-year publication summary
|
37
|
65
|
94
|
81
|
94
|
91
|
117
|
85
|
66
|
28
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Taisho Pharmaceutical Co., Ltd. | 857 |
30 |
| Takeda Pharmaceutical Company Limited | 2716 |
16 |
| F. Hoffmann-La Roche AG | 7841 |
12 |
| Pfizer Inc. | 3370 |
11 |
| H. Lundbeck A/S | 1240 |
11 |
| Novartis AG | 10341 |
10 |
| Janssen Pharmaceutica N.V. | 3226 |
10 |
| Demerx, Inc. | 76 |
10 |
| Research Triangle Institute | 416 |
9 |
| Altria Client Services LLC | 2369 |
8 |
| Daiichi Sankyo Company, Limited | 1892 |
8 |
| Mitsubishi Tanabe Pharma Corporation | 425 |
8 |
| Sage Therapeutics, Inc. | 334 |
8 |
| Shionogi & Co., Ltd. | 867 |
8 |
| Sunshine Lake Pharma Co., Ltd. | 619 |
8 |
| Neurosearch A/S | 156 |
8 |
| The Regents of the University of California | 20587 |
7 |
| AbbVie Deutschland GmbH & Co. KG | 256 |
7 |
| Sumitomo Dainippon Pharma Co., Ltd. | 211 |
7 |
| Gilgamesh Pharmaceuticals, Inc. | 64 |
7 |
| Other owners | 911 |